Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Slobodan Miric

Neurology Englewood, NJ Medical Doctor

NPI 1710908934 CMS profile 213109

401 South Van Brunt Street, Suite 203 Dr Miric Neurology Center, Englewood, NJ 07631

Open in the dashboard

General payments

$36,533

705 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Slobodan Miric of Englewood, NJ is reported in the CMS Open Payments database as having received $36,533 across 705 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,477 104
2024 General $2,101 103
2023 General $1,229 51
2022 General $9,727 102
2021 General $6,429 122
2020 General $13,352 88
2019 General $2,218 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Slobodan Miric
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Slobodan Miric were reported at $1,477. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Slobodan Miric Neurology median Middle half National median
2019 $2,218 $474 $118–$2,177 $163
2020 $13,352 $367 $82–$2,309 $114
2021 $6,429 $438 $104–$2,547 $132
2022 $9,727 $442 $103–$2,388 $149
2023 $1,229 $464 $119–$2,312 $160
2024 $2,101 $468 $119–$2,323 $164
2025 $1,477 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $12,927 37 payments
  2. AbbVie, Inc. $7,388 133 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $7,250 27 payments
  4. EMD Serono, Inc. $1,436 35 payments
  5. Supernus Pharmaceuticals, Inc. $1,203 51 payments
  6. Teva Pharmaceuticals USA, Inc. $661 48 payments
  7. Pfizer Inc. $650 74 payments
  8. Novartis Pharmaceuticals Corporation $643 56 payments
  9. Lilly USA, LLC $550 32 payments
  10. SK Life Science, Inc. $364 20 payments
  11. Other $3,460 192 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,671 18 payments
  2. Food and Beverage $10,883 678 payments
  3. Travel and Lodging $961 6 payments
  4. Education $19 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $12,416 27 payments
  2. NURTEC ODT Primary Care $7,478 53 payments
  3. UBRELVY Neuroscience $7,264 94 payments
  4. AIMOVIG $734 48 payments
  5. NURTEC ODT Pain $650 74 payments
  6. ZAVZPRET $650 74 payments
  7. OXTELLAR XR $594 3 payments
  8. QULIPTA $553 61 payments
  9. MAVENCLAD $545 16 payments
  10. EMGALITY $429 30 payments
  11. Other $5,364 324 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 114 drugs

Part D claims

5,566

Median for Neurology: 833

Drug cost

$2,242,435

Median for Neurology: $202,670

Branded share of claims

29.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 57 $737,698
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 94 $704,721
Aubagio Teriflunomide Brand 13 $119,548
Teriflunomide Generic 29 $72,934
Qulipta Atogepant Brand 54 $60,624
Nurtec Odt Rimegepant Sulfate Brand 47 $56,421
Ubrelvy Ubrogepant Brand 41 $53,011
Nourianz Istradefylline Brand 15 $49,320
Nuedexta Dextromethorphan Hbr/Quinidine Brand 24 $39,382
Rexulti Brexpiprazole Brand 25 $35,087

The 10 drugs with the highest cost, of 114 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$147,024

Medicare's payments for the services billed

Medicare patients

238

Average age 71

Services billed

1,287

128 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 60%
Diabetes 32%
Ischemic heart disease 32%
Alzheimer's or dementia 32%
Depression 28%
Chronic kidney disease 25%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$227 41 —
ZEPOSIA
$157 — —
BOTOX
$143 — —
QULIPTA
$112 54 —
KISUNLA
$104 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

705 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record